交易 Vir Biotechnology VIR

出售
 买入

VirBiotechnology 实时图表

5m 15m 30m 1h 4h 1d 1w

金融票据基础知识

Weekly Search
Weekly
Daily
日期 关闭 更改 更改(%)： 开盘价 高 低

VirBiotechnology news

最新新闻

显示更多
Ava Grace 2025 Aug 12, 03:20

US CPI Data July: A Risky Economic Outlook Unveiled

Australia inflation rate ticks up to 3.6% in April
Tommy Yap 2025 Aug 12, 02:23

Morning Note: RBA Rate Cut; US CPI Awaited; Ethereum Rallies on Inflows

Morning Note Cryptocurrencies Monetary Policy
Ghko B 2025 Aug 11, 16:00

Stock Market Today: Dow Fluctuates as Trump Extends China Tariff Deadline

Stocks
Sophia Claire 2025 Aug 11, 14:20

Indian Rupee Under Pressure: RBI Intervenes Amid Trade Tensions

Noah Lee 2025 Aug 11, 10:04

Israeli Minister Doubts Netanyahu's Ability to Achieve 'Decisive Victory' in Gaza

2025 Aug 11, 09:20

Trump-Putin Talks Spark Rally in Ukraine, Russia-Linked Assets

2025 Aug 11, 09:20

Europe Urges US to Ramp Up Russia Sanctions Before Trump-Putin Meeting

Sophia Claire 2025 Aug 11, 01:20

US Treasury Chief: Tariffs, Trade Imbalance, and the Fed's Future

信息

点差

0.03

点差(%)

0.7059 %

杠杆

1:10

隔夜利息（买入）

-0.0597 %

隔夜利息（卖出）

-0.0292 %

币种

USD

交易时间

市场关闭

星期二

13:31 - 19:59

星期一

13:31-19:59

星期三

13:31-19:59

星期四

13:31-19:59

星期五

13:31-19:59

分析和统计

开盘价

---

昨收

---

52 周高点/低点

--- – ---

市值

594560512

在外流通股份

138916000

财报日（下一）

0000-00-00

股息收益率

除息日

远期年度股息率

0

远期年股息率

0

每股收益

-4.01

详细了解此金融票据

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

相关金融票据

资产
出售
买入
更改(%)：

立即交易

立即交易

立即交易

立即交易
相关金融票据

latest_education_articles

显示更多
Markets.com Support Team 2024 Nov 29, 03:00

如果你在 2010 年以每枚 $0.10 投資了 $100 的比特幣，今天您的資產將高達驚人的 9,570 萬美元！

Markets.com Support Team 2024 Nov 20, 17:00

狗狗幣的瘋狂旅程

Markets.com Support Team 2024 Nov 08, 17:00

交易員趨勢：狗狗幣

Trustpilot